- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
LITESPARK-003 Trial Insights: Updates from ESMO 2023
An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).
EP: 1.Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers
EP: 2.Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023
EP: 3.Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape
EP: 4.ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer
EP: 5.Key Highlights from EV-302 Study at ESMO 2023
EP: 6.LITESPARK-003 Trial Insights: Updates from ESMO 2023
EP: 7.Future Opportunities in Genitourinary Cancers
This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.
Daneshmand discusses results from the LITESPARK-003 phase 2 trial evaluating belzutifan plus cabozantinib in advanced RCC. Belzutifan is a HIF-2α inhibitor approved for Von Hippel–Lindau disease–associated RCC. The LITESPARK-003 trial had 2 cohorts; cohort 1 was first-line, and cohort 2 was subsequent line therapy.
Cohort 1 included 50 patients with favorable risk, whereas cohort 2 had 51 patients with intermediate/poor risk. At a median follow-up of 2 years in cohort 1 and 40 months in cohort 2, median overall survival was not reached in cohort 1 and was 26.7 months in cohort 2. The combination showed antitumor activity and was fairly well tolerated, with no treatment-related deaths.
Daneshmand notes that although these are exciting results, determining the optimal place for belzutifan combinations within the evolving RCC treatment landscape of multiple combinations therapies remains to be seen. Nonetheless, having additional active targeted therapy options is positive.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
